Home / MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) Lyophilized Peptide

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) Lyophilized Peptide

Mitochondrial-Derived Peptide (MDP) – Regulates Metabolic Homeostasis, Glucose Metabolism, and Physical Performance
MOTS-c is a 16-amino acid mitochondrial-derived peptide (sequence: MRWQEMGYIFYPRKLR) encoded within the mitochondrial 12S rRNA region. Unlike most signaling peptides, MOTS-c is encoded by mitochondrial DNA and translocates to the nucleus in response to metabolic stress. It acts as a hormone-like regulator that improves insulin sensitivity, enhances glucose uptake in skeletal muscle, and promotes browning of white adipose tissue. Research suggests MOTS-c may counteract age-related metabolic decline and physical inactivity. This lyophilized powder is intended for subcutaneous or intraperitoneal injection after reconstitution
Quantity
ADD TO CART
BUY IT NOW
  • Detail

    1. Composition
    Active ingredient: MOTS-c peptide (acetate salt). 

    2. Appearance
    White to off-white lyophilized powder or cake. After reconstitution: clear, colorless solution.

    3. Available Strengths (Research Vials)

    • 10 mg/vial

    • 20 mg/vial

    • 40 mg/vial

    4. Molecular Information

    • Sequence: MRWQEMGYIFYPRKLR (16 amino acids)

    • Molecular Formula: C₉₁H₁₃₈N₂₆O₂₂S (theoretical)

    • Molecular Weight: ~2,060 g/mol

    • Purity (research grade): ≥95% (typically >98% by HPLC)

    5. Mechanism of Action
    MOTS-c functions as a cellular stress response signal:

    • Enters the nucleus and binds to the AHR (aryl hydrocarbon receptor) pathway

    • Increases intracellular AMP/ATP ratio, activating AMPK

    • Enhances insulin sensitivity and glucose uptake in skeletal muscle

    • Promotes browning of white adipose tissue (increases UCP-1 expression)

    • Attenuates age-dependent physical decline and metabolic dysfunction

    • Improves exercise capacity and mitochondrial function

    6. Research Indications (Not Clinical)
    Current research focuses on:

    • Metabolic syndrome and type 2 diabetes

    • Age-related metabolic decline

    • Insulin resistance

    • Obesity and thermogenesis

    • Skeletal muscle function and physical performance

    • Longevity and mitochondrial health

    Not approved for:

    • Human treatment of any disease

    • Weight loss in healthy individuals

    • Performance enhancement in sports

    7. Reconstitution
    Solvent: Sterile water for injection or bacteriostatic water (recommended for multi-use)

    Procedure:

    1. Add calculated volume to vial (e.g., 1 mL into 5 mg → 5 mg/mL)

    2. Swirl gently – do not shake violently (peptide is sensitive to aggregation)

    3. Allow to dissolve completely before use – solution should be clear

    Note: MOTS-c is relatively stable but avoid repeated vortexing or foaming.

    8. Dosing Reference (Research Use Only – Animal Models)

    Species Route Frequency Dose Range
    Mouse Intraperitoneal (IP) 5–14 days 5–10 mg/kg/day
    Mouse Subcutaneous (SC) 5–14 days 5–10 mg/kg/day
    In vitro Cell culture N/A 1–50 µM

    Human research equivalent (estimated for reference – NOT clinical recommendation):
    Some exploratory studies have used ~10–20 mg subcutaneously, 2–3 times per week. No established human dose exists.

    9. Storage

    Condition Temperature Duration
    Lyophilized powder (long term) -20°C 24 months
    Lyophilized powder (short term) 2–8°C 3–6 months
    Reconstituted solution (bacteriostatic water) 2–8°C 7–14 days
    Reconstituted solution (sterile water) 2–8°C 24–48 hours

    Protect from light. Do not freeze reconstituted solution.

    10. Reported Research Effects (Selected Studies)

    Effect Model Reference Finding
    Insulin sensitivity Aged mice Restored insulin sensitivity comparable to young mice
    Glucose homeostasis Diet-induced obese mice Reduced fasting glucose and improved glucose tolerance
    Browning of WAT Obese mice Increased UCP-1 expression and thermogenesis
    Exercise capacity Young mice Improved running endurance
    Myoblast differentiation C2C12 cells Enhanced differentiation and glucose uptake
    Longevity Mouse model Attenuated age-associated metabolic decline

    11. Adverse Reactions / Toxicity Profile (Research Data)

    • Well-tolerated in animal studies at therapeutic doses

    • No observed cytotoxicity in cell studies at relevant concentrations

    • High doses in animal models (e.g., 50 mg/kg) may cause mild injection site reactions

    • Long-term safety data are limited

    12. Contraindications

    • Known hypersensitivity to MOTS-c or any excipient

    • Active malignancy (metabolic pathways involved in cancer progression – caution advised)

    • Pregnancy or breastfeeding (no safety data)

    • Severe renal or hepatic impairment (no research data)

    13. Warnings and Precautions

    • For research use only – not FDA or EMA approved

    • Not for human therapeutic use or self-administration

    • Limited human safety data available

    • May interact with metabolic pathways; use caution in diabetes research subjects

    • Not for athletic performance enhancement – peptide hormones are generally prohibited by WADA

    • Discontinue if any unexpected adverse reaction occurs

  • Customer Reviews
    No comments
BACK